Department of Dermatology and Wound Healing, Cardiff University, UK.
Br J Dermatol. 2012 Oct;167(4):888-900. doi: 10.1111/j.1365-2133.2012.11154.x. Epub 2012 Sep 18.
Congenital erythropoietic porphyria (CEP) is an autosomal recessive photomutilating porphyria with onset usually in childhood, where haematological complications determine prognosis. Due to its extreme rarity and clinical heterogeneity, management decisions in CEP are often difficult.
To develop a management algorithm for patients with CEP based on data from carefully characterized historical cases.
A single investigator collated data related to treatments and their outcomes in 29 patients with CEP from the U.K., France, Germany and Switzerland.
Six children were treated with bone marrow transplantation (BMT); five have remained symptomatically cured up to 11.5 years post-transplantation. Treatments such as oral charcoal, splenectomy and chronic hypertransfusion were either of no benefit or were associated with complications and negative impact on health-related quality of life. Lack of consistent genotype-phenotype correlation meant that this could not be used to predict disease prognosis. The main poor prognostic factors were early age of disease onset and severity of haematological manifestations.
A management algorithm is proposed where every patient, irrespective of disease severity at presentation, should receive a comprehensive, multidisciplinary clinical assessment and should then be reviewed at intervals based on their predicted prognosis, and the rate of onset of complications. A BMT should be considered in those with progressive, symptomatic haemolytic anaemia and/or thrombocytopenia. Uroporphyrinogen III synthase genotypes associated with poor prognosis would additionally justify consideration for a BMT. Rigorous photoprotection of the skin and eyes from visible light is essential in all patients.
先天性红细胞生成性卟啉症(CEP)是一种常染色体隐性光畸形卟啉症,通常在儿童时期发病,血液学并发症决定预后。由于其极为罕见和临床异质性,CEP 的治疗决策往往较为困难。
根据精心描述的历史病例数据,为 CEP 患者制定管理算法。
一名调查员收集了来自英国、法国、德国和瑞士的 29 名 CEP 患者的治疗方法及其结果的数据。
6 名儿童接受了骨髓移植(BMT)治疗;其中 5 名在移植后 11.5 年仍无症状缓解。口服活性炭、脾切除术和慢性高输血等治疗方法要么没有效果,要么会导致并发症,对健康相关生活质量产生负面影响。缺乏一致的基因型-表型相关性意味着无法据此预测疾病预后。主要的不良预后因素是疾病发病年龄较早和血液学表现严重程度。
提出了一种管理算法,即无论患者在发病时的严重程度如何,都应接受全面的多学科临床评估,然后根据其预测的预后和并发症发生的速度进行定期复查。对于有进行性、症状性溶血性贫血和/或血小板减少症的患者,应考虑进行 BMT。与预后不良相关的尿卟啉原 III 合酶基因型将进一步证明 BMT 的合理性。所有患者都必须严格进行皮肤和眼睛的光防护,避免可见光照射。